Search results for "Pope"

showing 10 items of 92 documents

Effect of Age and Lipoperoxidation in Rat and Human Adipose Tissue-Derived Stem Cells

2020

A wide range of clinical applications in regenerative medicine were opened decades ago with the discovery of adult stem cells. Highly promising adult stem cells are mesenchymal stem/stromal cells derived from adipose tissue (ADSCs), primarily because of their abundance and accessibility. These cells have multipotent properties and have been used extensively to carry out autologous transplants. However, the biology of these cells is not entirely understood. Among other factors, the regeneration capacity of these cells will depend on both their capacity of proliferation/differentiation and the robustness of the biochemical pathways that allow them to survive under adverse conditions like thos…

AdultMaleHomeobox protein NANOGAgingTime FactorsStromal cellArticle SubjectApoptosisBiologyRegenerative MedicineBiochemistryRegenerative medicineCell therapyAMP-Activated Protein Kinase KinasesPeptide Elongation Factor 2Sirtuin 1SOX2AnimalsHumansRats WistarLipoperoxidation.Cell ProliferationQH573-671SOXB1 Transcription FactorsStem CellsMesenchymal stem cellAge FactorsCell DifferentiationMesenchymal Stem CellsNanog Homeobox ProteinCell BiologyGeneral MedicineMiddle AgedRatsCell biologyOxidative StressAdipose TissueageFemaleLipid PeroxidationStem cellCytologyProtein KinasesResearch ArticleHeLa CellsAdult stem cell
researchProduct

Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry

2009

Patients surviving invasive fungal disease (IFD) and needing further antineoplastic chemotherapy are at high risk of recurrent fungal infection. In the absence of randomised controlled trials in this area, secondary prophylactic regimens are diverse. From 448 patients registered with the Multinational Case Registry of Secondary Antifungal Prophylaxis, we performed an analysis of patients receiving caspofungin (CAS) or itraconazole (ITC). All patients had an underlying haematological malignancy and had been diagnosed with an episode of IFD earlier in their course of treatment. Data collected comprised demographics, underlying disease, first episode of IFD, antifungal prophylaxis, incidence a…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsAdolescentItraconazoleAspergillosisChemopreventionEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundCaspofunginInternal medicinemedicineHumansAspergillosisPharmacology (medical)RegistriesMycosisAgedFirst episodebusiness.industryIncidence (epidemiology)Stem cell transplantationGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTransplantationTreatment OutcomeInfectious DiseasesMycoseschemistryHematologic NeoplasmsChemoprophylaxisFemaleAntifungal prophylaxisItraconazoleCaspofunginbusinessmedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Caspofungin for the treatment of candidaemia in patients with haematological malignancies

2010

AbstractThis study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 × 109/L) for a median of 12 days (2–41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6–26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as …

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsNeutropeniaDrug-Related Side Effects and Adverse ReactionsCandidaemia; Caspofungin; Leukaemiamedicine.medical_treatmentAntineoplastic AgentsNeutropeniaEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundPharmacotherapyCandidaemiaCaspofunginInternal medicinemedicineHumansLeukaemiaProspective StudiescaspofunginProspective cohort studyMycosisFungemiaAgedChemotherapyHematologybusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeInfectious DiseaseschemistryHematologic NeoplasmsleukaemiaFemaleCaspofunginbusinessFungemia
researchProduct

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

2007

Summary Background Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis. Methods We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentLipoproteinsAmphotericin B/ therapeutic useMicrobial Sensitivity TestsLipoproteins/ therapeutic usePeptides CyclicEchinocandinsLipopeptideschemistry.chemical_compoundDouble-Blind MethodAmphotericin BInternal medicineAmphotericin BPeptides Cyclic/ therapeutic usemedicineHumansAdverse effectMycosisFungemiaCandidiasis/complications/ drug therapy/microbiologyAPACHEAgedddc:616Aged 80 and overVoriconazolebusiness.industryAntifungal Agents/ therapeutic useCandidiasisMicafunginGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseApacheSurgeryTreatment OutcomechemistryMicafunginFemaleCaspofunginbusinessFluconazolemedicine.drugThe Lancet
researchProduct

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Res…

2010

Caspofungin at standard dose was evaluated as first-line monotherapy of mycologically documented probable/proven invasive aspergillosis (IA) (unmodified European Organisation for Research and Treatment of Cancer/Mycosis Study Group criteria) in allogeneic hematopoietic SCT patients. The primary efficacy end point was complete or partial response at end of caspofungin treatment. Response at week 12, survival and safety were additional end points. Enrollment was stopped prematurely because of low accrual, with 42 enrolled and 24 eligible, giving the study a power of 85%. Transplant was from unrelated donors in 16 patients; acute or chronic GVHD was present in 15. In all, 12 patients were neut…

AdultMalemedicine.medical_specialtyAntifungal AgentsDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationAspergillosischemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultPharmacotherapyCaspofunginInternal medicineMedicineAspergillosisHumansTransplantation HomologousaspergillosiscaspofunginAdverse effectSurvival rateAgedallogeneicTransplantationbusiness.industryHematopoietic Stem Cell Transplantationhematopoietic SCTHematologyMiddle Agedmedicine.diseaseSurgeryCalcineurinTransplantationEuropeSurvival RateTreatment OutcomechemistryDrug Therapy CombinationFemaleCaspofunginbusinessBone marrow transplantation
researchProduct

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

2011

To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken.Adverse event data were pooled worldwide from 17 clinical efficacy and safety studies. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 5.0.In the pooled clinical trial data set, 3028 patients received at least one dose of micafungin. The mean age of patients was 41.4 years; with 296 (9.8%) children (16 years) and 387 (12.8%) elderly patients (≥ 65 years). Common underlying conditions were hematopoietic stem cell and other transplantations (26.1%), malignancies (20.8%) and HIV (32.9%). Mean exposure was 18 days for adults and 29 days …

AdultMalemedicine.medical_specialtyAntifungal AgentsTime FactorsAdolescentDatabases FactualNauseaMedDRAEchinocandinsLipopeptidesYoung AdultInternal medicinemedicineHumansPharmacology (medical)ChildAdverse effectAgedAged 80 and overClinical Trials as TopicDose-Response Relationship Drugbusiness.industryAge FactorsMicafunginInfantGeneral MedicineMiddle AgedHypokalemiaSurgeryClinical trialDiarrheaMycosesChild PreschoolMicafunginVomitingFemalemedicine.symptombusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

Peptides of the Constant Region of Antibodies Display Fungicidal Activity

2012

Synthetic peptides with sequences identical to fragments of the constant region of different classes (IgG, IgM, IgA) of antibodies (Fc-peptides) exerted a fungicidal activity in vitro against pathogenic yeasts, such as Candida albicans, Candida glabrata, Cryptococcus neoformans, and Malassezia furfur, including caspofungin and triazole resistant strains. Alanine-substituted derivatives of fungicidal Fc-peptides, tested to evaluate the critical role of each residue, displayed unaltered, increased or decreased candidacidal activity in vitro. An Fc-peptide, included in all human IgGs, displayed a therapeutic effect against experimental mucosal and systemic candidiasis in mouse models. It is in…

Antifungal AgentsErythrocyteslcsh:MedicineImmunoglobulin Gchemistry.chemical_compoundEchinocandinsMiceCaspofunginCandida albicanslcsh:ScienceCandida albicansMice Inbred BALB CMultidisciplinarybiologyCandidiasisAnimal ModelsInfectious DiseasesMedicineFemaleMalasseziaImmunoglobulin Constant RegionsResearch ArticleImmunologyMycologyMicrobial Sensitivity TestsMicrobiologyHemolysisAntibodiesMicrobiologyLipopeptidesImmune systemModel OrganismsDrug Resistance FungalmedicineAnimalsHumansBiologyCryptococcus neoformansMalasseziaCandida glabratalcsh:RImmunityTriazolesbiology.organism_classificationmedicine.diseaseImmunoglobulin ADisease Models AnimalchemistryImmunoglobulin MImmunoglobulin Gbiology.proteinCryptococcus neoformanslcsh:QSystemic candidiasisCaspofunginPeptidesPLoS ONE
researchProduct

Alternative Biosynthetic Starter Units Enhance the Structural Diversity of Cyanobacterial Lipopeptides

2019

Puwainaphycins (PUWs) and minutissamides (MINs) are structurally analogous cyclic lipopeptides possessing cytotoxic activity. Both types of compound exhibit high structural variability, particularly in the fatty acid (FA) moiety. Although a biosynthetic gene cluster responsible for synthesis of several PUW variants has been proposed in a cyanobacterial strain, the genetic background for MINs remains unexplored. Herein, we report PUW/MIN biosynthetic gene clusters and structural variants from six cyanobacterial strains. Comparison of biosynthetic gene clusters indicates a common origin of the PUW/MIN hybrid nonribosomal peptide synthetase and polyketide synthase. Surprisingly, the biosynthet…

Antifungal AgentsGenetics and Molecular BiologyCyanobacteria01 natural sciencesApplied Microbiology and BiotechnologycyanobacteriaPeptides Cyclicbiosynteesi03 medical and health scienceschemistry.chemical_compoundLipopeptidesBiosynthesisAnti-Infective AgentsBacterial ProteinsNonribosomal peptidePolyketide synthaseGene clusterPeptide SynthasessyanobakteeritGene030304 developmental biology2. Zero hungerchemistry.chemical_classification0303 health sciencesNatural productEcologybiology010405 organic chemistryLipopeptideAnabaenaYeast0104 chemical scienceschemistryBiochemistrypeptiditGenes BacterialMultigene Familybiology.proteinpeptidesbiosynthesisPolyketide SynthasesFood ScienceBiotechnology
researchProduct

Isolation and characterization of Saccharomyces cerevisiae mutants resistant to aculeacin A

1991

Aculeacin A is a lipopeptide that inhibits beta-glucan synthesis in yeasts. A number of Saccharomyces cerevisiae mutants resistant to this antibiotic were isolated, and four loci (ACR1, ACR2, ACR3, and ACR4) whose products are involved in the sensitivity to aculeacin A of yeast cells were defined. Mutants containing mutations in the four loci were also resistant to echinocandin B, another member of this lipopeptide family of antibiotics. In contrast, acr1, acr3, and acr4 mutants were resistant to papulacandin B (an antibiotic containing a disaccharide linked to two fatty acid chains that also inhibits beta-glucan synthesis), but acr2 mutants were susceptible to this antibiotic. This result …

Antifungal AgentsLlevat de cervesaGenotypeMutantSaccharomyces cerevisiaePapulacandin BSaccharomyces cerevisiaemedicine.disease_causePeptides CyclicMicrobiologyFungal ProteinsEchinocandinschemistry.chemical_compoundCell WallEchinocandin BmedicinePharmacology (medical)PharmacologyFungal proteinMutationbiologyMutagenicity TestsMembrane ProteinsLipopeptideAminoglicòsidbiology.organism_classificationYeastAnti-Bacterial AgentsAminoglucòsidsAminoglycosidesInfectious DiseaseschemistryBiochemistryGlucosyltransferasesMutationSchizosaccharomyces pombe ProteinsPeptidesResearch Article
researchProduct

Characterization of the interaction of the antifungal and cytotoxic cyclic glycolipopeptide hassallidin with sterol-containing lipid membranes.

2019

Hassallidins are cyclic glycolipopeptides produced by cyanobacteria and other prokaryotes. The hassallidin structure consists of a peptide ring of eight amino acids where a fatty acid chain, additional amino acids, and sugar moieties are attached. Hassallidins show antifungal activity against several opportunistic human pathogenic fungi, but does not harbor antibacterial effects. However, they have not been studied on mammalian cells, and the mechanism of action is unknown. We purified hassallidin D from cultured cyanobacterium Anabaena sp. UHCC 0258 and characterized its effect on mammalian and fungal cells. Ultrastructural analysis showed that hassallidin D disrupts cell membranes, causin…

Antifungal AgentskolesteroliPeptideLipopeptide01 natural sciencesBiochemistrychemistry.chemical_compoundSTRUCTURE ELUCIDATIONCandida albicansMARINE CYANOBACTERIAmammalian cellsmembrane1183 Plant biology microbiology virologychemistry.chemical_classification0303 health sciencesCell DeathMembraneGlycopeptidesLipopeptideHERBICOLIN-ADEHYDROPEPTIDE LACTONEAmino acidSterolsCholesterolMembraneBiochemistrysolunsalpaajatMitochondrial Membranesmedicine.symptomBacterial outer membraneBiophysicsmechanismAntineoplastic Agentssaponin digitoninMolecular dynamicsCyanobacteriaITURIN-A03 medical and health sciencesLipopeptidesMembrane LipidsNATURAL-PRODUCTSCell Line TumormedicineHumansPropidium iodidesyanobakteerit030304 developmental biologyantimikrobiset yhdisteet010405 organic chemistryMAJOR COMPONENTCell BiologyluonnonaineetAnabaenaSterol0104 chemical sciencesMechanism of actionchemistrylipopeptidepeptiditMOLECULAR-DYNAMICS1182 Biochemistry cell and molecular biologyDrug Screening Assays AntitumorGlycolipidsBiochimica et biophysica acta. Biomembranes
researchProduct